INO vs. SGHT, TLSI, ANGO, UTMD, NPCE, RCEL, TMCI, GUTS, TCMD, and PROF
Should you be buying Inovio Pharmaceuticals stock or one of its competitors? The main competitors of Inovio Pharmaceuticals include Sight Sciences (SGHT), TriSalus Life Sciences (TLSI), AngioDynamics (ANGO), Utah Medical Products (UTMD), NeuroPace (NPCE), AVITA Medical (RCEL), Treace Medical Concepts (TMCI), Fractyl Health (GUTS), Tactile Systems Technology (TCMD), and Profound Medical (PROF). These companies are all part of the "surgical & medical instruments" industry.
Sight Sciences (NASDAQ:SGHT) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, community ranking, dividends, risk and profitability.
Sight Sciences has a net margin of -67.18% compared to Sight Sciences' net margin of -16,238.91%. Inovio Pharmaceuticals' return on equity of -44.45% beat Sight Sciences' return on equity.
Inovio Pharmaceuticals received 702 more outperform votes than Sight Sciences when rated by MarketBeat users. Likewise, 71.49% of users gave Inovio Pharmaceuticals an outperform vote while only 31.91% of users gave Sight Sciences an outperform vote.
55.5% of Sight Sciences shares are held by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are held by institutional investors. 27.1% of Sight Sciences shares are held by company insiders. Comparatively, 2.5% of Inovio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Sight Sciences has a beta of 2.73, meaning that its share price is 173% more volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500.
In the previous week, Inovio Pharmaceuticals had 29 more articles in the media than Sight Sciences. MarketBeat recorded 30 mentions for Inovio Pharmaceuticals and 1 mentions for Sight Sciences. Inovio Pharmaceuticals' average media sentiment score of 1.75 beat Sight Sciences' score of 0.27 indicating that Sight Sciences is being referred to more favorably in the media.
Sight Sciences presently has a consensus target price of $4.70, indicating a potential downside of 11.99%. Inovio Pharmaceuticals has a consensus target price of $70.67, indicating a potential upside of 488.89%. Given Sight Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than Sight Sciences.
Sight Sciences has higher revenue and earnings than Inovio Pharmaceuticals.
Summary
Sight Sciences beats Inovio Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Inovio Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inovio Pharmaceuticals Competitors List
Related Companies and Tools
